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Mucin-type O-glycosylation is the most abundant type of O-
glycosylation. It is initiated by the members of the polypeptide
N-acetyl--galactosaminyltransferase (ppGalNAc-T) family
and closely associated with both physiological and pathological
conditions, such as coronary artery disease or Alzheimer’s dis-
ease. The lack of direct and selective inhibitors of ppGalNAc-Ts
has largely impeded research progress in understanding the
molecular events in mucin-type O-glycosylation. Here, we
report that a small molecule, the plant flavonoid luteolin, selec-
tively inhibits ppGalNAc-Ts in vitro and in cells. We found that
luteolin inhibits ppGalNAc-T2 in a peptide/protein-competi-
tive manner but not promiscuously (e.g. via aggregation-based
activity). X-ray structural analysis revealed that luteolin binds to
the PXP motif– binding site found in most protein substrates,
which was further validated by comparing the interactions of
luteolin with wild-type enzyme and with mutants using 1H
NMR– based binding experiments. Functional studies disclosed
that luteolin at least partially reduced production of -amyloid
protein by selectively inhibiting the activity of ppGalNAc-T iso-
forms. In conclusion, our study provides key structural and
functional details on luteolin inhibiting ppGalNAc-T activity,
opening up the way for further optimization of more potent and
specific ppGalNAc-T inhibitors. Moreover, our findings may
inform future investigations into site-specific O-GalNAc glyco-
sylation and into the molecular mechanism of luteolin-medi-
ated ppGalNAc-T inhibition.
Mucin-type O-glycosylation (hereafter also referred to as
O-GalNAc5 glycosylation) is the most abundant type of O-gly-
cosylation and is closely relevant in physiological and patholog-
ical conditions, such as coronary artery disease (1), familial
tumoral calcinosis (2), and Alzheimer’s disease (3, 4). It has
been clearly demonstrated that O-GalNAc glycosylation of
amyloid precursor protein (APP) is important for its cell surface
localization, endocytosis, and the production of amyloid  (A)
(5–7), which is the primary component of the parenchymal
amyloid deposits in Alzheimer’s disease (8). In mammals,
O-GalNAc glycosylation is initiated by a family of 20 polypeptide
N-acetyl--galactosaminyltransferases (ppGalNAc-Ts) (9, 10).
These enzymes transfer GalNAc from the donor substrate, uridine
diphosphate N-acetyl--galactosamine (UDP-GalNAc), to an
acceptor substrate protein, forming GalNAc-Ser/Thr (also
known as the Tn antigen), and release the free UDP (9) (Fig.
1A). The acceptor substrate specificities of these isoforms are
distinct but partly overlapping (11–13). This is reflected by
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increasing evidence that different ppGalNAc-Ts could also
elicit distinct biological outcomes (14). The site-specific O-Gal-
NAc glycans on proteins catalyzed by different ppGalNAc-T
isoforms are closely related with protein processing, stability,
and secretion (14). Change of O-GalNAc glycans on specific
sites of protein substrates, such as angiopoietin-like protein 3
(ANGPTL3) or APP, is deeply involved in coronary artery dis-
ease or Alzheimer’s disease (1, 4, 7, 15). Therefore, develop-
ment of ppGalNAc-T inhibitor could provide a useful tool for
research on the molecular mechanism of O-GalNAc glycosyla-
tion in human development and disease.
Whereas several small molecules are reported to perturb
O-GalNAc glycosylation in cells (16 –18), such as the uridine
derivative 1-68A and GalNAc analogue Ac5GalNTGc, most of
these compounds are donor substrate derivatives (16, 18). We
have described UDP-GalNAc derivatives that acted as poor
binders of ppGalNAc-T2 (19). Recently, a mixed-mode selec-
tive inhibitor of ppGalNAc-T3 has been reported (17). Natural
products and approved drugs are structurally diverse and have
well-characterized bioactivity, safety, and pharmacological
function. Luteolin is an effective ingredient and natural product
found in African and Chinese traditional herbal medicines with
safe profiles (20, 21). As a flavonoid, several co-crystal studies
revealed that luteolin interacts with protein kinase, tankyrases,
receptors, etc. (22–27). However, it is unknown whether luteo-
lin could affect protein O-glycosylation.
In this context, we identified luteolin as a direct protein sub-
strate-competitive inhibitor of ppGalNAc-T2. The competitive
nature of this flavonoid versus peptide substrates was also sup-
ported by the crystal structure of ppGalNAc-T2 in complex
with UDP and luteolin, which allowed us to pinpoint the fla-
vonoid in the peptide-binding groove and in particular where
the PXP motif (where X is usually a small hydrophobic residue)
of protein substrates is recognized. The location of luteolin was
also supported by 1H NMR binding experiments. Moreover, we
found that luteolin reduced the production of A through
selectively inhibiting ppGalNAc-Ts, which provided a putative
molecular mechanism of luteolin in reducing the Alzheimer’s
disease pathologies.
Results
Identification of luteolin as an inhibitor of ppGalNAc-T2 that
reduces O-GalNAc glycosylation in cells
Luteolin was initially identified to be an inhibitor of ppGal-
NAc-T2 from 4757 agents, including 1659 Food and Drug
Administration–approved drugs and 3098 natural products
and synthetic compounds, by a newly developed high-
throughput screening assay for ppGalNAc-T2 (data not
shown). Following validation with the HPLC-based ppGal-
NAc-T assay (28 –30), we found that luteolin could inhibit
ppGalNAc-T2 catalytic activity with an IC50 of 15 M
using EA2 peptide (PTTDSTTPAPTTK) as acceptor sub-
strate (Fig. 1B). ppGalNAc-T2 is ubiquitously expressed in a
variety of cells, and several structural studies revealed that
EA2 is an effective substrate of ppGalNAc-T2 (31–33).
To evaluate whether luteolin had specific inhibition against
O-GalNAc glycosylation in cells, first, we detected the meta-
bolic labeling of GalNAz (N-azido-acetylgalactosamine) in
CHO-ldlD cells with or without luteolin treatment by using
click chemistry. CHO-ldlD is an O-GalNAc glycosylation–
deficient cell line due to the lack of the epimerase that converts
UDP-Glc/GlcNAc to UDP-Gal/GalNAc (34), and then the
extra addition of peracetylated N-azidoacetylgalactosamine
(Ac4GalNAz) in the cell culture will lead to specific formation
of GalNAz modification (35). We incubated CHO-ldlD cells
with Ac4GalNAz and treated with or without the indicated con-
centrations of luteolin. The cells were collected for click-chem-
istry reaction and analyzed by streptavidin blotting. We found
that luteolin showed a dose-dependent inhibitory effect on the
GalNAz signal, indicating a potent inhibitory effect of luteolin
on O-GalNAc glycosylation in cells (Fig. 1C).
Next, we investigated the inhibitory selectivity of luteolin in
several cell lines. Three lectins, namely Jacalin (which binds to
Gal 1–3GalNAc, GalNAc; O-GalNAc glycans), Helix pomatia
agglutinin (HPA; binds to -linked terminal GalNAc), and con-
canavalin A (ConA; binds to high mannose), were used. Lectin
blots of total lysates of HEK 293T cells showed a substantial
reduction in the Jacalin signal but not ConA signal (Fig. 1D). In
Jurkat cells, immunofluorescence detection indicated that lute-
olin could also suppress the HPA but not ConA signal on the
cell surface (Fig. 1E). These results demonstrated that luteolin
selectively reduced the global levels of O-GalNAc glycosylation
in cells. In agreement with the results above, we detected the
inhibitory effects of luteolin on the endogenous APP, a typical
O-GalNAc glycosylated protein (5, 7), in HEK 293T cells and
A549 cells. We found that luteolin could significantly reduce
the ratio of the high-molecular weight band of APP (APP-H;
O-GalNAc-glycosylated APP (7)) with a 75 and 80% reduction
in HEK 293T cells and A549 cells, respectively (Fig. 1, F and G).
Meanwhile, we transfected APP and another typical O-GalNAc
glycosylated protein podoplanin (PDPN) (36) in HEK 293T
cells to test the inhibitory effects of luteolin. After luteolin treat-
ment, the APP-H and its Jacalin signal were significantly
decreased (Fig. 1H). In contrast, there was little change in
APP-L (non-O-GalNAc glycosylated APP) or ConA signal (Fig.
1H). Besides APP, luteolin treatment also led to a shift of PDPN
to a lower molecule weight, which is consistent with the effect
of O-GalNAc glycan depletion (37) (Fig. 1I). Meanwhile, a sim-
ilar expression level of ppGalNAc-T2 was observed in HEK
293T treated with or without luteolin, suggesting that the
inhibitory effects of luteolin should not be attributed to the
alteration in the ppGalNAc-T2 expression (Fig. 1, H and I).
Those experiments suggested that luteolin exhibited selective
inhibition toward O-GalNAc glycosylation on proteins in cells.
Luteolin is a selective and protein substrate-competitive
inhibitor of ppGalNAc-T2
Flavonoids have been reported as a family of molecules with
multiple targets through promiscuous mechanism, in particu-
lar due to colloidal aggregation (38). To rule out this possibility
on the inhibitory effects of luteolin against ppGalNAc-T2 in
our enzyme system, dynamic light scattering (DLS) analysis and
spin-down experiments were performed. The DLS analysis
showed that the particles in the 50 –1000-nm size of luteolin
were gradually reduced with the increased addition of Triton
Luteolin inhibits ppGalNAc-Ts
























X-100 and almost undetectable when Triton X-100 reached
0.2% (Fig. 2A and Fig. S1). Then the spin-down experiments
using our ppGalNAc-T assay containing 0.2% Triton X-100 also
showed that the inhibition of luteolin against ppGalNAc-T2 had
no significant difference after centrifugation (Fig. 2B). These
results strongly suggested that the inhibition of luteolin on
Figure 1. Luteolin functions as a potent inhibitor in vitro and in cells. A, schematic representation of the initiation of O-GalNAc glycosylation by ppGalNAc-
Ts. B, chemical structure and IC50 of luteolin against ppGalNAc-T2 detected by HPLC-based ppGalNAc-T assay. The data are expressed as percentages of the
control (DMSO, 100%) and are shown as the mean  S.D. (n  3). C, effects of luteolin on the O-GalNAc glycosylation in CHO-ldlD cells detected by the metabolic
labeling and click chemistry. CHO-ldlD cells were preincubated with 100 M Ac4GalNAz for 12 h and then treated with the indicated concentrations of luteolin
for an additional 36 h. Total cell lysates were collected to react with biotin alkyne for 3 h before being analyzed by streptavidin blotting. D, effects of luteolin on
glycans of proteins in HEK 293T cells. Cells were incubated with luteolin at 25 M for 36 h, and total lysates were analyzed by lectin blot. Control, DMSO-treated
cells. E, effects of luteolin on glycans in Jurkat cells detected by immunofluorescence. Cells were treated with 25 M luteolin for 24 h and stained with different
lectins. Green, HPA and ConA; blue, nuclei stained with DAPI. Scale bars, 50 m. Control, DMSO-treated cells. F and G, effects of luteolin on the glycosylation of
endogenous APP in HEK 293T cells (F) and A549 cells (G). Cell were incubated with 25 M luteolin for 36 h and collected and analyzed by Western blotting. L,
long-term exposure; S, short-term exposure. H and I, effects of luteolin on the glycosylation of transfected APP (H) and PDPN (I) in HEK 293T cells. FLAG-tagged
APP and PDPN were transfected for 24 h and then incubated with 25 M luteolin for another 24 h. APP was then immunoprecipitated from the cell lysates (Input)
using an anti-FLAG M2 affinity resin. The mean density of APP-H or PDPN-H was quantified and normalized with APP-L or PDPN-L. Cells expressing APP or PDPN
without luteolin treatment were considered 100%. IP, immunoprecipitation. 50 g of total protein was used to analyze endogenous APP, and 10 g was used
for transfected APP and PDPN. The data shown represent the mean  S.D. (error bars) (n  3). *, p  0.05; **, p  0.01; ***, p  0.001. F–I, two-tailed Student’s
t test. -Actin and -tubulin were used as loading control. EV, empty vector.
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ppGalNAc-T2 with 0.2% Triton X-100 was not due to the
aggregation-based mechanism.
To address the inhibitory mechanism of luteolin on ppGal-
NAc-T2, we performed enzyme kinetics assays (Fig. 2, C and D).
The enzyme kinetics experiments showed that luteolin exhib-
ited competitive inhibition with respect to EA2 substrate (Ki
1.4 M; Fig. 2C) and non-competitive inhibition with respect
to the UDP-GalNAc (Ki 4.1 M; Fig. 2D). Luteolin bound
100-fold more to ppGalNAc-T2 than the EA2 peptide did to
ppGalNAc-T2 (Km 160 M; Fig. 2E).
Prompted by the potent inhibition of luteolin on ppGalNAc-
T2, we also measured the IC50 values of luteolin in the presence
of various peptide substrates and ppGalNAc-T isoforms. We
found out that luteolin displayed poor substrate selectivity (Fig.
2E and Fig. S2). In addition to ppGalNAc-T2, we also evaluated
the effect of luteolin on other members of ppGalNAc-T family
and human O-GlcNAc transferase (OGT) (39 – 41). Luteolin
inhibited with similar IC50 values (low micromolar values)
members of both subfamilies Ib and Ic (42), such as ppGalNAc-
T14 (note that ppGalNAc-T2 also belongs to the Ib subfamily)
Figure 2. Kinetics and selectivity analyses of luteolin inhibition mechanism on ppGalNAc-T2. A, the change of percentage of particles in the 50 –1000-nm
size range with luteolin and different concentrations of Triton X-100 (v/v). The size of particles was measured by DLS. B, spin down experiments for luteolin in
our HPLC-based ppGalNAc-T assay with 0.2% Triton X-100 (v/v). Enzyme reactions were performed before or after centrifugation (16,000  g, 1 h). The data are
expressed as percentages of the control (DMSO, 100%). Data above are shown as the mean  S.D. (error bars) (n  3). Two-tailed Student’s t test was used; n.s.,
no significant difference. C, luteolin shows competitive inhibition (Ki  1.4  0.05 M) with respect to EA2 substrate in the presence of 1200 M UDP-GalNAc.
D, UDP-GalNAc showed non-competitive inhibition (Ki  4.1  1.1 M) in the presence of 1200 M EA2. The concentration of luteolin was 0 M (●), 5 M (Œ),
10 M (f), and 20 M (). E, kinetics parameter of luteolin inhibition on ppGalNAc-T2 with various peptide substrates and the selectivity of luteolin within the
ppGalNAc-T family with EA2 peptide. a, competitive inhibition constant; b, non-competitive inhibition constant. The data shown in E are represented as
mean  S.D. (n  3).
Luteolin inhibits ppGalNAc-Ts
























and ppGalNAc-T3/T6, respectively, whereas it showed a more
potent inhibition on ppGalNAc-T10 (subfamily IIb) with an
IC50 of 1.7 M (Fig. 2E and Fig. S2). In contrast to the effects on
these ppGalNAc-Ts, luteolin displayed a poor inhibition on
ppGalNAc-T1 and T13, two ppGalNAc-Ts from subfamily Ia
with high homology between their amino acid sequences (Fig.
2E and Fig. S2). Likewise, luteolin had little effect on OGT
either. These results suggested that luteolin displayed selective
inhibition on ppGalNAc-Ts from subfamilies Ib, Ic, and IIb and
was a poor inhibitor of subfamily Ia and other distant glycosyl-
transferases, such as OGT (Fig. 2E).
X-ray structure and 1H NMR binding experiments of ppGalNAc-
T2/mutants with luteolin
To further elucidate the luteolin-binding mode, we obtained
crystals of ppGalNAc-T2 in complex with UDP/Mn2 that
were subsequently soaked with the flavonoid. Crystals of the
complex diffracted to a resolution of 2.3 Å, which allowed us to
build a final model with good refinement statistics (Table S1).
Consistent with the above kinetics data, the crystal structure
revealed that this flavonoid bound to the peptide-binding
groove (Fig. 3A). The presence of UDP in the active site at a
distance of 8 Å from luteolin also supported the non-compet-
itive character of this flavonoid versus UDP-GalNAc inferred
from kinetics data (Fig. 2D).
A closer inspection of the luteolin-binding site revealed that
the flavonoid is sandwiched between 6, the loop between 6
and 7, 8, and the flexible loop between 10 and 11 (Fig. S3).
The compound is also close to the lectin domain from the
neighboring monomer present in the asymmetric unit (AU).
Note that in these orthorhombic crystals, six molecules of
ppGalNAc-T2 are arranged in three independent dimers in the
AU (33). However, luteolin only accomplishes direct interac-
tions with residues located in the peptide-binding groove of one
of the monomers, ruling out the potential contribution of the
lectin domain of the neighboring ppGalNAc-T2 to the binding
of the flavonoid (Fig. S4). Although dimers have been described
by small-angle X-ray scattering experiments (32), it is not clear
whether this particular crystallographic dimer is present in
solution because part of the peptide-binding groove is partly
occluded by residues of the neighboring monomer, impeding
the binding of long peptides to the enzyme (33). A more
detailed evaluation of the binding site reveals that the flavonoid
competes specifically with the PXP motif found on most pro-
tein substrates (Fig. 3A). The PXP motif– binding site is formed
by Phe361, Phe280, and Trp282, which are conserved residues
among the ppGalNAc-T isoenzymes. These are key residues in
the recognition of common peptide motifs, such as Pro-X-Pro
(where X is usually a small hydrophobic residue) found in acceptor
substrates (31, 32). The 5,7-dihydroxy-4-chromenone ring is
engaged in parallel and edge-to-face - interactions with Trp282
and Phe361, respectively, and -CH interactions with Val255 (Fig.
3A). Phe361 also establishes CH- interactions with the dihydroxy-
phenyl moiety. In addition, there are direct hydrogen bonds
between the 7-hydroxyl group and Ile253 backbone and water
molecule–mediated hydrogen bonds between the 5-hydroxyl
group and Ser267 backbone, the 3-hydroxyl group and Phe361/
Lys363, and the oxygen ring and Trp282 (Fig. 3A). The 7-hy-
droxyl group also interacts with an ethylenglycol molecule,
which is located in a hydrophobic pocket formed by Ala266,
Ile252, Ile253, Leu270, Ile301, and Ile351 (Fig. 3A).
The AU also depicted the presence of two additional luteolin
molecules (Fig. 3B) with less defined density compared with the
one displayed in Fig. 3A. The 5,7-dihydroxy-4-chromenone
adopted almost identical positions (atomic shift average of 0.62
Å; Fig. 3C), whereas the dihydroxyphenyl moiety was more flex-
ible (atomic shift average of 1.50 Å; Fig. 3C). Overall, the major
interactions with the enzyme are conserved, whereas the water
molecule-mediated hydrogen bonds between Trp282 and resi-
dues of the flexible loop are lost (Fig. 3A), supporting again the
flexibility and the potential weaker binding affinity of the
dihydroxyphenyl moiety in opposition to the chromenone
ring. Strikingly, luteolin can only access the active form of
ppGalNAc-T2 (Fig. 3D), which suggests that the flexible loop
must adopt its closed conformation, leading to the unblocking
of the PXP motif binding site and consequently allowing the
entrance of luteolin (Fig. 3D).
To further validate the location of luteolin inferred from the
crystal structure, 1H NMR experiments were conducted. 1H
NMR spectra were recorded to compare the effect of binding on
the luteolin signal broadening (43– 45). Due to its low solubility,
luteolin concentration was set to 250 M (final concentration of
DMSO was 8%). Samples with different protein concentrations
were assayed. However, the best results were obtained at 2.5 M
in the presence of 50 M UDP and MnCl2.
Fig. 3E and Fig. S5 shows the 1H spectra of free luteolin and
luteolin with ppGalNAc-T2 wild type and the mutants W282A
and F463A. When ppGalNAc-T2 wild type is incubated with a
solution containing luteolin, all signals become broad and less
intense due to tight binding to the protein. However, no signal
broadening was observed when luteolin was in the presence of
the W282A mutant, implying that a significant decrease of the
affinity is achieved. This supports the crystal structure where
the benzopyronic moiety interacts with Trp282. In the sample
containing luteolin and the mutant F463A (located in the lectin
domain from the neighboring ppGalNAc-T2), the broad signals
indicate strong binding with the protein, suggesting that the
lectin domain from the neighboring monomer forming the
dimer in the asymmetric unit does not interact with this fla-
vonoid. Note that Phe463 is the closest residue to luteolin com-
ing from the lectin domain of the neighboring ppGalNAc-T2.
Structure–function analysis of luteolin analogue inhibition on
ppGalNAc-T2
Considering that flavonoid has drawn great attention for its
beneficial effect (46), we further examined the inhibitory effects
of another 16 flavonoid analogues (Fig. 4). Most of them
showed 10% inhibition on the activity of ppGalNAc-T2 at 50
M in our HPLC-based ppGalNAc-T assay, suggesting that the
inhibition on ppGalNAc-T2 is only achieved by specific fla-
vonoids. To explore the structure and activity relationship of
luteolin, we also compared the inhibitory effects of flavonoid
analogues with or without these hydroxyl groups. For example,
isorhamnetin and chrysoeriol, which contained bulkier sub-
stituents at position 3 in the B ring, exhibited poor inhibitory
effect; fisetin, which had no OH-5 in the A ring, exhibited no
Luteolin inhibits ppGalNAc-Ts
























Figure 3. X-ray structure and 1H NMR binding experiments of ppGalNAc-T2/mutants with luteolin. A, view (left) of the luteolin-binding site of the
ppGalNAc-T2UDP-luteolin complex. The crystal structure of ppGalNAc-T2 in complex with UDP and MUC5AC-13 (32) is shown for comparison purposes (inset).
A surface representation (right) of the ppGalNAc-T2UDP-luteolin complex depicts the pocket present in these enzymes. Part of the residues forming the
luteolin-binding site and the pocket are shown in gray, whereas residues of the flexible loop are depicted in yellow. Luteolin/MUC5AC-13 and UDP are shown
as green and brown carbon atoms, respectively. Ethylene glycol is shown as gray carbon atoms, whereas water molecules are depicted as red spheres. Hydrogen
bond interactions are shown as dotted deep olive lines. Electron density maps are Fo 	 Fc syntheses (blue) contoured at 2.2  for luteolin. B, view of the two
additional luteolin molecules present in the AU. C, overlay of the ppGalNAc-T2 molecules in complex with luteolin showing the flexibility mainly in the
dihydroxyphenyl moiety. Luteolin and Trp282/Phe361 are depicted as green, yellow, and brown carbon atoms. D, overlay of one of the monomers containing
luteolin with ppGalNAc-T2 inactive form in complex with UDP (Protein Data Bank entry 2FFV (31)) and ppGalNAc-T2 inactive form in complex with MUC5AC-
Cys13 (Protein Data Bank entry 5AJN (32)). This figure shows that luteolin has steric hindrance with both inactive forms of ppGalNAc-T2. The flexible loop for the
active and inactive forms is shown in yellow and blue/brown, respectively. E, 1H NMR spectra were recorded to compare the effect of binding on the luteolin
signal broadening. Shown are 1H NMR spectra of free luteolin and luteolin with ppGalNAc-T2 wild type and the mutants W282A and F463A.
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inhibitory effect at 50 M and only 20% effects when we raised
its amount to 200 M. Both OH-3 and OH-5 do not make
direct interactions with the enzyme but are engaged in water-
mediated hydrogen bonds with the enzyme, explaining their
importance in the inhibitory effects on ppGalNAc-T2. In addi-
tion, bulkier substituents at position 3 might cause the desta-
bilization of the flexible loop (Figs. 3A and 4), explaining the
lack of potency of these compounds. Other flavonoids, such
as rhoifolin, which contains a polar dissacharide coupled to
the 7-hydroxyl group in the A ring, is a poor inhibitor of ppGal-
NAc-T2. In this case, the sugar moiety might cause steric hin-
drance with residues within the pocket or lead to the destabili-
zation of the hydrophobic pocket (Figs. 3A and 4).
Although rutin, quercitrin, and myricitrin have both hydroxyl
groups, they also bear large substituents in position 3 of the C
ring as sugar moieties that greatly reduced their inhibitory
potency (Fig. 4). In these compounds, the breaking of the pla-
narity between the chromenone and phenyl rings (47), imposed
Figure 4. Structure–function analysis of luteolin analogues using an HPLC-based ppGalNAc-T assay with EA2 peptide. a, the IC50 are calculated as
percentages of the control (DMSO, 100%) and shown as the mean  S.D. (n  3). b, the inhibitory ratio (%) was calculated with the positive control (DMSO, 0%)
(50 M compounds). c, isorhamnetin did not show any inhibitory activity at 200 M. d, the inhibitory ratio of fisetin at 200 M is 23.87  0.4%. N.I., no inhibition.
Luteolin inhibits ppGalNAc-Ts
























by the sugar moieties, might lead to constraints in the structural
disposition of the rings. This might disfavor an optimal inter-
action with Trp282 and Phe361 or cause steric hindrance with
the mobile flexible loop, which might explain why these com-
pounds are poor inhibitors of ppGalNAc-T2. On the contrary,
quercetin or myricetin, luteolin-like compounds containing
small substituents in position 3 of the C ring, rendered similar
inhibitory potencies to luteolin, suggesting not only that these
flavonoids adopted a similar structure as luteolin but also that
the 3-hydroxyl group or small substituents in this position did
not contribute to the binding of the enzyme (Figs. 3A and 4).
Luteolin selectively inhibits the catalytic activity of
ppGalNAc-Ts on APP in cells
Luteolin exhibited enzyme selectivity on EA2 peptide in the
in vitro enzyme assay, which led us to investigate whether it also
has same selectivity in cells. Luteolin has been reported to
reduce A production in an Alzheimer’s disease (AD) model
mouse (48, 49). APP is the precursor of A and also is a well-
known O-GalNAc– glycosylated protein in AD (5–7, 50).
Therefore, we chose APP as a protein substrate to test the spec-
ificity and selectivity of luteolin in cells.
We transiently co-expressed APP and different ppGalNAc-
Ts into HEK 293T cells and treated the cells with luteolin (Fig.
5A). We found that all of the tested ppGalNAc-Ts could glyco-
sylate APP, but the bands of O-GalNAc glycosylated APP
(APP-H bands) for each ppGalNAc-Ts were different. Luteolin
decreased the APP-H bands catalyzed by ppGalNAc-T2 or T3
but not by T1 or T13 (Fig. 5A), suggesting that luteolin selec-
tively inhibited ppGalNAc-T isoforms in cells. To further con-
firm this observation, we synthesized three peptides from APP
as the acceptor substrates for ppGalNAc-T activity assay (Fig. 5,
B and C). These peptides contained the dominant glycosylation
sites (Thr291, Thr292, Thr576, and Thr577 for APP695; Thr353 for
APP770), which have been reported to be crucial for APP pro-
cessing (7, 50). An HPLC-based ppGalNAc-T assay showed
that both peptide 1 and peptide 3 could be efficiently glycosy-
lated by ppGalNAc-T2 and ppGalNAc-T3, whereas ppGal-
NAc-T1 showed very weak catalytic activity toward them (Fig.
5C). Peptide 2 could be only catalyzed by ppGalNAc-T3. ppGal-
NAc-T13 could not glycosylate all of the three peptides (Fig.
5C). This result is consistent with the report of Kong et al. (12)
and clearly indicated that ppGalNAc-T isoforms have different
preference for glycosylation sites on APP. Here, ppGalNAc-
T13 may glycosylate other sites in cells that are not covered in
our peptides, such as sequential triple T (28, 29) on APP. Fur-
thermore, upon treatment with luteolin, the product peaks on
these peptides resulting from the ppGalNAc-T2 and ppGal-
NAc-T3 were largely blocked (Fig. 5C). However, there was no
big difference in the peak produced by ppGalNAc-T1 after lute-
olin treatment (Fig. 5C). Moreover, we also co-expressed
ppGalNAc-T1, ppGalNAc-T2, and APP in HEK 293T cells and
treated them with luteolin. The inhibitory effects of luteolin on
the ppGalNAc-T2– catalyzed O-GalNAc glycans on APP could
be masked by co-expressing ppGalNAc-T1 (Fig. 5D). These
results are consistent with our observations in Figs. 2E and 5A
and indicate that luteolin blocked the glycosylation on APP by
inhibiting specific ppGalNAc-T isoforms not only in the in vitro
enzyme assay but also in cells.
In addition to luteolin, we also compared the inhibitory
effects of its analogues on the ppGalNAc-T2, using APP as the
protein substrate in the cell. Luteolin and quercetin showed
pronounced inhibition (Fig. 5E). However, fisetin, acacetin,
rutin, and isorhamnetin had no effect on the O-GalNAc glyco-
sylation of APP (Fig. 5E), which is consistent with our crystal
structure and structure–function analysis (Figs. 3A and 4). The
results above suggest that luteolin could selectively inhibit the
activity of certain ppGalNAc-Ts on APP in cells.
Decrease in O-GalNAc glycosylation by luteolin substantially
reduces the generation of A
O-GalNAc glycosylation has been reported to influence APP
processing (4, 6, 7), so we wondered whether the inhibition of
ppGalNAc-T by luteolin could affect A production. We
treated the Swedish-mutation APP stable cell line (HEK 293T-
APP Swe cell) with luteolin and found that the production of
APP-H and the amounts of total A, A40, and A42 were
decreased in a dose-dependent manner (Fig. 6, A and B). Mean-
while, the sAPP and sAPP were also decreased as A (Fig.
6B). Then we tested whether the reduction of A was due to the
decreased level of its O-GalNAc glycosylation. We analyzed the
levels of A in the CHO-K1 cells and its O-GalNAc glycan–
deficient derivative CHO-ldlD cells. The O-GalNAc glycosyla-
tion of proteins was different in various cell lines (51). Notably,
only one band of APP was observed in CHO-K1 and CHO-ldlD
cells, suggesting that the amount of O-GalNAc glycosylation of
APP in CHO-K1 and CHO-ldlD cells may be lower than that in
HEK 293T cells. The immunoprecipitation analysis with Jacalin
clearly demonstrated that the APP was glycosylated in the
CHO-K1 cells but not in CHO-ldlD cells (Fig. 6C). Consistent
with the effects in HEK 293T cells, we found that luteolin led to
a significant decrease in the O-GalNAc glycans on APP and A
production in CHO-K1 cells (Fig. 6, C and D). However, the A
generation in transfected CHO-ldlD cells was at least 60% lower
than that in CHO-K1 cells (Fig. 6D). After the restoration of
O-GalNAc glycosylation by adding exogenous Gal and GalNAc
into CHO-ldlD cell culture medium, the production of A was
partly enhanced (Fig. 6, E and F). However, luteolin largely
decelerated the restoration process in both O-GalNAc glycosyl-
ation and A production (Fig. 6, E and F). The total A, A40,
and A42 were reduced 30% by luteolin treatment with 800
M Gal and GalNAc (Fig. 6, E and F). Additionally, we also
treated APP/PS1 transgenic mice with luteolin at a dose of 50
mg/kg/day for 2 months and checked the O-GalNAc glycosyl-
ation level on APP and A production in their brain homoge-
nates. We found that the O-GalNAc glycosylation signal on
APP was significantly reduced, as indicated by the immunopre-
cipitation analysis (Fig. 7A). The amounts of soluble A40 and
A42 in the brains of APP/PS1 mice were reduced by nearly
30% (Fig. 7B). This preliminarily suggested that luteolin could
affect O-GalNAc glycosylation of APP in mice. Taken together,
these results suggested that decreased O-GalNAc glycosylation
is a pivotal mechanism for the reduction of A production after
luteolin treatment.
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Considering the increasing evidence for the involvement of
ppGalNAc-Ts in the regulation of normal physiological functions
as well as pathogenesis of various diseases (9, 14, 52), direct and
bioactive ppGalNAc-T inhibitors could serve as useful tools for
research and may have beneficial therapeutic effects for the treat-
ment of some diseases. In this study, we reported for the first time
that luteolin could directly inhibit ppGalNAc-Ts in a protein/pep-
tide substrate–competitive manner and show selectivity in the
ppGalNAc-T family. Additionally, we put forward that luteolin
reduced the A production at least partially by decreasing the
O-GalNAc glycosylation via selectively inhibiting the activity of
ppGalNAc-T isoforms, providing a putative mechanism for lute-
olin in modulating Alzheimer’s disease pathologies.
Figure 5. Luteolin could inhibit the catalytic activity of ppGalNAc-Ts on APP in cells. A, effects of luteolin on the glycosylation on APP in HEK 293T cells
overexpressing ppGalNAc-T1, T2, T3, or T13. FLAG-tagged APP alone or together with T1, T2, T3, or T13 were transfected into cells for 24 h before treating with
20 M luteolin for an additional 24 h. The cell lysates were collected and analyzed for APP. B, schematic diagrams of synthesized APP-derived peptides.
O-GalNAc glycosylation sites are marked with black dots (7). KPI, Kunitz-type protease inhibitor domain; OX2, OX2 domain (7); , , and , cleavage sites of -,
-, and -secretases. C, luteolin (50 M) can inhibit the glycosylation on APP-derived peptides catalyzed by ppGalNAc-T2 or T3. S, substrate peak; P, product
peak. D, ppGalNAc-T1 attenuates the inhibitory effect of luteolin on O-GalNAc glycosylation of APP catalyzed by T2. E, effects of luteolin analogues on the
O-GalNAc glycosylation of APP catalyzed by ppGalNAc-T2. For D and E, different combinations of APP, ppGalNAc-T2, or ppGalNAc-T1 plasmids were trans-
fected into HEK 293T cells and then treated with the indicated compounds (20 M) and analyzed as in A. For A, D, and E, the mean density of APP-H was
quantified and normalized with APP-L and compared with the control (DMSO-treated cells co-transfected with APP and ppGalNAc-Ts without luteolin
treatment, 100%). The data shown in A, D, and E represent mean  S.D. (error bars) (n  3). *, p  0.05; **, p  0.01; ***, p  0.001; two-tailed Student’s t test for
A and one-way ANOVA for D and E. EV, empty vector.
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ppGalNAc-T2 is a membrane-bound protein that needs
detergent to make itself into an active state (53). Luteolin could
aggregate in solution, leading to promiscuous inhibition in the
absence of detergent. Our experiments proved that in our reac-
tion system with 0.2% Triton X-100, luteolin did not function as
an aggregate-based mechanism. In addition, based on our
kinetic and crystal structure analysis, we clearly demonstrated
that luteolin exhibited a classical competitive inhibitory mech-
anism against ppGalNAc-T2.
Our inhibition kinetics and X-ray structural demonstrated
that luteolin acted as a protein substrate– competitive inhibitor
of the ppGalNAc-T2 active form and competed specifically
with the PXP motif present in most protein substrates (Fig. 3).
The structure together with 1H NMR experiments also revealed
that two major residues, Trp282 and Phe361, contribute mainly
to the binding and are responsible for the likely better affinity
of the chromenone ring in opposition to the more flexible dihy-
droxyphenyl ring. The structure also provided the discovery of
Figure 6. Luteolin reduces the O-GalNAc glycosylation on APP and leads to a decrease of A production in cells. A and B, dose-dependent effect of
luteolin on the O-GalNAc glycosylation of APP and A production in HEK 293T-APP Swe cells. Cells were incubated with luteolin for 24 h and then lysed and
blotted for APP. The mean density of APP-H was quantified and normalized with APP-L and presented as percentages of control (DMSO, 100%). A, sAPP, and
sAPP in the cell medium above were quantified by ELISA and normalized to the amount of total protein and presented as percentages of control (cells without
luteolin treatment, 100%). C, effects of luteolin on O-GalNAc glycans of APP in CHO-K1 and CHO-ldlD cells. Cells were transfected with FLAG-tagged APP for 24 h
followed by incubation with 25 M luteolin for an additional 24 h. APP was then immunoprecipitated and detected by Jacalin staining. D, As in the cell medium
above were analyzed by ELISA. Control, CHO-K1 cells expressing APP without luteolin treatment, 100%. E, adding exogenous Gal and GalNAc restores the
O-GalNAc glycosylation on APP in CHO-ldlD cells, but these effects could be attenuated by luteolin treatment (25 M). F, As in the cell medium above were
quantified by ELISA and represented as A (pg) per total protein (mg). E, DMSO treatment; ●, 25 M luteolin treatment. The mean density of Jacalin in C and
E was quantified and normalized with APP and presented as a percentage of control (cells without luteolin treatment, 100%). Data represent mean  S.D. (error
bars), n  3. *, p  0.05; **, p  0.01; ***, p  0.001; for A, one-way ANOVA; for A in B, D, and F, two-way ANOVA; for sAPP and sAPP in B, C, and E, two-tailed
Student’s t test. IP, immunoprecipitation; EV, empty vector.
Luteolin inhibits ppGalNAc-Ts
























a druggable pocket that might lead to the design and synthesis
of more potent luteolin derivatives containing hydrophobic
moieties in the 7-hydroxyl group or in position 6 of the chrom-
enone ring. A combination of the crystal structure analysis
together with the structure–inhibition relationship studies of
the flavonoids on ppGalNAc-T2 provided more insights into
the structural features responsible for an optimal inhibition and
offered other exploitable positions in luteolin for the design of
more potent compounds (e.g. the OH-3 might be modified
with polar groups to replace the water molecule visualized in
the crystal structure, maximizing the interaction with the flex-
ible loop).
Although several co-crystal studies showed that luteolin
could also interact with other enzymes/proteins (22–27), there
exists some difference between the interaction of luteolin with
ppGalNAc-T2 and with other targets. The characteristics of the
surrounding amino acids are also quite different. Utilizing the
differential interaction of luteolin with ppGalNAc-T2 and
other targets could greatly contribute to the development of a
specific inhibitor.
The enzymatic activity assay in vitro and in cells showed that
luteolin behaved as a pan-inhibitor of different ppGalNAc-Ts
isoforms, including subfamilies Ib, Ic, and IIb (Fig. 2E). The key
Trp (Trp282 in ppGalNAc-T2) establishing - interactions
with the 5,7-dihydroxy-4-chromenone ring is conserved in all
above ppGalNAc-Ts except for ppGalNAc-T10, which con-
tains an Arg instead (Arg296). This residue might be engaged in
a stronger cation- interaction with the larger ring of luteolin,
which can explain why ppGalNAc-T10 is the most sensitive to
luteolin. However, it was not expected that luteolin showed a
poor inhibition of subfamily Ia (Fig. 2E), because a closer eval-
uation of multiple sequence alignments and structural conser-
vation analysis between ppGalNAc-T2 and the above isoforms
revealed that the luteolin-binding site was more conserved
between subfamilies Ia and Ib as compared with the members
of Ic and IIb subfamilies (42). This suggested that other more
complex features, such as the differences in the mobility of the
flexible loop between different ppGalNAc-Ts, which in turn
will probably depend on the surrounding residues, might
account for the different selectivity of luteolin versus different
isoforms.
The inhibitory effect of luteolin on the total level of O-Gal-
NAc glycosylation in cells was modest. This is very likely to be
due to the selective inhibition of luteolin in ppGalNAc-Ts. Each
ppGalNAc-T isoform has overlapping and unique substrate
specificity. Despite the modest inhibition on O-GalNAc glyco-
sylation in cells, our work paved the way for further optimiza-
tion based on the scaffold of luteolin to develop selective ppGal-
NAc-T inhibitor. Recently, increasing evidence indicates the
importance of some specific glycosylation sites on certain gly-
coprotein during disease progression (13, 51). O-GalNAc gly-
cosylation is universal and important even for the normal cells.
Complete abolishment of O-GalNAc glycosylation may lead to
side effects on cells. Therefore, the clear selectivity of luteolin in
ppGalNAc-Ts may serve as a potential candidate for further
studies of the site-specific inhibition of O-GalNAc glycosyla-
tion on disease-associated glycoproteins. In that context, a
modest inhibitory effect at the total level in cells will not be an
obstacle for its further application.
The excess generation of A is regarded as a contributor to
the dysfunction and degeneration of neurons that occurs in AD
(8). APP is the precursor of A, and O-GalNAc glycosylation of
APP is needed for its cell localization and endocytosis and plays
critical roles in the A production (4, 6, 7). In this study, we
proved that ppGalNAc-T isoforms have different preference
for glycosylation sites on APP, and luteolin selectively inhibited
a set of ppGalNAc-T isoforms including ppGalNAc-T2 and T3,
but not ppGalNAc-T1 and ppGalNAc-T13, both in vitro and in
cells (Fig. 5). Moreover, our restoration experiments with exog-
enous Gal and GalNAc in CHO-ldlD cells indicated that luteo-
lin treatment significantly inhibited O-GalNAc glycosylation
on APP and then led to the reduction of A in cells (Fig. 6).
These findings are in line with previous reports (48, 49). There-
fore, we inferred that luteolin may reduce the A production at
least partially by selectively inhibiting the activity of ppGal-
NAc-T isoforms. Because luteolin might also reduce the O-Gal-
NAc glycosylation levels on other glycoproteins apart from
APP, we cannot rule out other potential mechanisms of action
for the reduction of A. Actually, the sAPP and sAPP were
also reduced as A (Fig. 6B) of HEK 293T-APP Swe cells with
luteolin treatment, so we inferred that luteolin acted on APP
and affected APP secretion before the activity of -, -, and
-secretase. It is possible that luteolin may regulate APP trans-
porting out of the Golgi. Further experiments were needed to
settle this issue. Nevertheless, we have proved that the O-Gal-
NAc glycosylation inhibition is an important mechanism for
Figure 7. The change of O-GalNAc glycosylation of APP and A production in APP/PS1 transgenic mice with luteolin treatment. A, the O-GalNAc
glycosylation of APP in extracts from brain homogenates was analyzed by immunoprecipitation (IP) of anti-APP antibody (C-T15). The mean density of Jacalin
was quantified. B, soluble As from brain homogenates of mice were detected by ELISA. Data are presented as a percentage of control (PBS-treated mice,
100%) and shown as mean  S.D. (error bars) (n  3 for Jacalin staining and n  5 for A detection). *, p  0.05; **, p  0.01; two-tailed Student’s t test.
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luteolin in modulating AD pathologies, which may also appli-
cable for other diseases such as cancer or inflammation.
In summary, although luteolin has been reported as interact-
ing with several targets (22–27), we for the first time show lute-
olin could directly inhibit ppGalNAc-Ts and reduce A pro-
duction by decreasing the O-GalNAc glycosylation. Our study
represents a candidate scaffold structure for further optimiza-
tion to develop specific ppGalNAc-T inhibitor. Considering
that luteolin exhibited selectivity in ppGalNAc-T isoforms, fur-
ther optimization based on this specific flavonoid may provide
potent inhibitors to explore site-specific O-GalNAc glycosyla-




UDP-GalNAc, GalNAc, and Gal were purchased from Sigma-
Aldrich (Steinheim, Germany). EDTA and manganese chloride
were from Sinopharm (Shanghai, China). EA2 and other pep-
tides were synthesized by Scilight-Peptide (Beijing, China).
Luteolin was from PI & PI Technology (Guangdong, China) in
the highest purity available as powder.
Cloning, expression, and purification of recombinant enzymes
The putative catalytic region and lectin domain of ppGal-
NAc-T2 (amino acids 52–571) were amplified by high-fidelity
PCR and cloned into the pFLAG-CMV-3 expression vector
(Sigma) as described previously (10, 28 –30). FLAG-tagged
ppGalNAc-T2 was expressed in HEK 293T cells, and the
recombinant enzyme was purified from the cell medium using
anti-FLAG M2 affinity gel (Sigma). Similarly, recombinant
human ppGalNAc-T1 (amino acids 34 –559), T3 (amino acids
50 – 633), T6 (amino acids 53– 622), T10 (amino acids 34 – 604),
T13 (amino acids 40 –556), and T14 (amino acids 39 –552) were
cloned and purified in the same way. The purity of recombinant
ppGalNAc-Ts was tested by silver staining.
For the ppGalNAc-Ts used in the cellular experiments, full-
length ppGalNAc-Ts were cloned into vector-pcDNA3.1 and
detected with Myc antibody in the lysates (Abmart, Shanghai,
China).
HPLC-based ppGalNAc-T activity assay
This assay used a FAM-labeled EA2 peptide as the substrate
and was performed as described previously (30). The reaction
mixture contained the following components in a final volume
of 20 l: 10 ng of ppGalNAc-T2, 100 M EA2, 100 M UDP-
GalNAc, 0.2% Triton X-100 (v/v), 5 mM MnCl2, and 0.5 l of
DMSO or the tested compound in 25 mM HEPES buffer (the
concentrations of both substrates approximate to the Km).
Under these conditions, the mixture was incubated at 37 °C for
30 min, during which the reaction rates were linear. The reac-
tion mixture was boiled at 95 °C for 5 min to terminate the
reaction and then separated by reverse-phase HPLC (Shi-
madzu, Kyoto, Japan) using the C18 analytical column (COS-
MOSIL 5C18-AR-II, 4.6  250 mm). The experiments were
independently performed in triplicate, and the activity of the
positivecontrol(DMSO)wasdefinedas100%.Inthedosedepen-
dence experiments, selected compounds were tested at the
indicated concentrations, and IC50 values were obtained using
GraphPad Prism version 5 software.
Similarly, the inhibitory activity of luteolin on ppGalNAc-
T1, T3, T6, T10, T13, or T14 in the presence of the substrate
EA2 peptide (mono-GalNAc EA2 peptide for T10 (30)) and
on ppGalNAc-T2 in the presence of the peptide substrate
Muc1a (FAM-AHGVTSAPDTR), Muc5AC (SAPTTSTT-
SAPTK-FAM), or Muc7 (PTPSATTPAPPSSSAPPETTAAK-
FAM) was accordingly measured under the same conditions.
Kinetic analysis
To explore the mode of action of luteolin on ppGalNAc-T2,
kinetic analysis was performed using the HPLC-based ppGal-
NAc-T assay described above. The reaction rate was deter-
mined with ppGalNAc-T2 at the indicated concentrations of
luteolin in the presence of increasing concentrations of EA2
(0 –1200 M) with 1200 M UDP-GalNAc or in the presence of
increasing concentrations of UDP-GalNAc (0 –1200 M) with
1200 M EA2. The data were fitted using the Michaelis–
Menten equation to determine the values of Ki or Ki using
GraphPad Prism version 5. To illustrate the type of inhibition
(competitive, non-competitive, or mixed-type inhibition), the
data were analyzed via replots of the slopes of Lineweaver–Burk
plots against varying inhibitor concentrations (Fig. 2, C and D).
Purification of ppGalNAc-T2, crystallization, structure
determination, and refinement
ppGalNAc-T2 was expressed in the SMD1168 Pichia pasto-
ris strain and purified using the purification protocol described
previously (33). Crystals of the ppGalNAc-T2 were grown by
hanging-drop experiments at 18 °C through mixing 1 l of pro-
tein solution (a mix formed by 7 mg/ml ppGalNAc-T2, 5 mM
UDP, and 5 mM MnCl2 in 25 mM Tris, pH 8, 0.5 mM EDTA, and
1 mM tris(2-carboxyethyl) phosphine with an equal volume of a
reservoir solution (10% PEG 8000, 6% ethylene glycol, 100 mM
Hepes, pH 7). Under these conditions, crystals appeared within
2 days, and they were soaked overnight in a solution containing
7.5 mM luteolin (the final DMSO concentration was 5%), 10%
PEG 8000, 6% ethylene glycol, 100 mM HEPES, pH 7. Then the
crystals were cryo-protected with 25% ethylene glycol, 10%
PEG 8000, 100 mM HEPES, pH 7, and frozen in a nitrogen gas
stream cooled to 100 K. Processing and scaling were performed
as before (33). The crystal structure was solved and refined as
explained previously for identical crystals (33).
NMR experiments
NMR samples were prepared in perdeuterated 25 mM TRIS-
d11 in deuterated water, 7.5 mM NaCl, 1 mM -mercaptoetha-
nol, uncorrected, pH 7.4, 50 M UDP, 50 M MnCl2, and 8%
deuterated dimethyl sulfoxide. Luteolin was solved at 250
M. The final concentration of the wild-type protein and
mutants was 2.5 M. Experiments were performed on a
Bruker AVANCE 500-MHz spectrometer, provided with a
TBO probe head, and temperature was set at 303 K. Proton
spectra were recorded with solvent suppression (Bruker
sequence zgesgp), the residual signal of HDO (hydrogen
deuterium oxide) (4.70 ppm) was used for referencing chem-
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ical shifts (see Fig. S5), and only the aromatic region is
shown. Luteolin 1H NMR (D2O, 500 MHz):  (ppm) 6.16 (s,
1H, HA), 6.43 (s, 1H, HB), 6.56 (s, 1H, HC), 6.94 –7.00 (m, 1H,
HE), 7.41–7.49 (m, 2H, HD, HF). The mutants W282A and
F463A were introduced by site-directed mutagenesis by
GenScript and using the template pPICZAgalnact2 (Lys75–
Gln571). Both proteins were expressed and purified as the
wild-type enzyme (33).
Cell culture and transfection
HEK 293T-APP Swedish mutant cells (HEK 293T-APP Swe;
a generous gift from Dr. Yaer Hu) were maintained in DMEM
(Life Technologies, Inc., Carlsbad, CA), 10% FBS (Life Technol-
ogies), 1% (w/v) penicillin and streptomycin (Life Technolo-
gies), and 200 g/ml G418 (Life Technologies) in a humidified
5% CO2 atmosphere at 37 °C as described previously (54). Wild-
type HEK 293T and Jurkat cells were cultured in DMEM and
RPMI 1640 (Life Technologies), respectively, supplemented
with 10% FBS or 1% penicillin and streptomycin. Chinese ham-
ster ovary (CHO-K1) cells and CHO-ldlD cells were cultured in
DMEM/F-12 (Life Technologies).
Plasmids containing human ppGalNAc-T1, T2, T3, or T13
or FLAG-tagged wild-type APP695 (FLAG-tagged APP) were
transfected into HEK 293T cells using X-treme GENE 9 DNA
Transfection Reagent (Roche Applied Science, Mannheim,
Germany) according to the manufacturer’s instructions.
Evaluation of the activity of ppGalNAc-T in cells by using click
chemistry to capture GalNAz-labeled proteins
CHO-ldlD cells were incubated with 100 M Ac4GalNAz
(Thermo) for 12 h before treatment with the indicated concen-
trations of luteolin for another 36 h. After the incubation, cells
were lysed in 50 mM Tris-HCl buffer (pH 7.4) containing 1%
Triton X-100, and the extracted proteins were quantified by a
BCA protein assay (Pierce). 1 mg of cell lysate was mixed with
20 M biotin alkyne (Invitrogen) and a mixture of catalysts in
PBS (pH 7.5) and rotated for 3 h at 25 °C. The ingredients of
catalyst were 0.5 mM tert-butyl-2,2,2-trichloroacetimidate
(Sigma), 2 mM L-ascorbic acid sodium salt (Sinopharm Chemi-
cal Reagent Inc.), and 1 mM CuSO45H2O (Sigma). Biotin-la-
beled proteins were then subjected to 10% SDS-PAGE and blot-
ted with strepavidin (LI-COR Biosciences, Lincoln, NE).
Western blot and immunoprecipitation (IP)
Cells were collected and lysed in 50 mM Tris-HCl buffer (pH
7.4) containing 1% Triton X-100 or 1% Nonidet P-40, 150 mM
NaCl, and 1 protease inhibitor mixture (Roche Applied Sci-
ence). The extracted proteins were quantified by a BCA protein
assay (Pierce). Equal amounts of protein were subjected to 10%
SDS-PAGE, transferred to membranes (GE Healthcare), and
blotted with the indicated antibodies: anti-APP C terminus
antibody (C-T15, Sigma), anti-FLAG antibody against FLAG-
tagged APP or PDPN (Sigma), anti-Myc antibody against Myc-
tagged ppGalNAc-Ts (Abmart), anti-ppGalNAc-T2 antibody
(Sigma), and anti--actin antibody or -tubulin antibody
(Sigma).
The immunoprecipitation of FLAG-tagged and endogenous
APP was performed by incubating 1 mg of total protein with
anti-FLAG affinity resin (Sigma) or C-T15 (Sigma), respec-
tively, at 4 °C overnight. The C-T15– bound proteins were
immunoprecipitated for 3 h at 4 °C using Protein A–agarose
beads (Roche Applied Science). The agarose beads were then
washed three times with TBS, and the bound proteins were
eluted with 2 Laemmli buffer. The resuspended proteins were
subjected to Western blot analysis.
Lectin blot
The cell lysates were separated by 10% SDS-PAGE and trans-
ferred to cellulose acetate membranes (GE Healthcare). The
membranes were washed with PBS containing 1% Tween 20 at
room temperature before incubation with the Jacalin (primarily
recognizing O-GalNAc glycans) and concanavalin A (ConA;
primarily recognizing N-glycans) lectin conjugated with HRP
(Vector Laboratories, Burlingame, CA) in 0.1% Tween 20 –PBS
buffer at 4 °C overnight. The blots were visualized by ECL
(Pierce).
Fluorescence imaging
After incubation with DMSO or luteolin at the indicated
concentrations, Jurkat cells were collected and fixed on cover-
slips using Cytospin (Thermo, San Jose, CA). The fixed cells
were treated with 4% paraformaldehyde (Sangon Biotech,
Shanghai, China) for 30 min at room temperature, washed with
PBS, blocked with 5% BSA (Sangon Biotech) in PBS for 1 h at
room temperature, and incubated with HPA (primarily recog-
nizing O-GalNAc glycans) and ConA lectin conjugated with
FITC (Vector Laboratories) at 4 °C overnight. The cells were
then incubated with 0.5 ml of DAPI (1.25 g/ml) for 3 min and
washed three times in PBS before acquiring images using an
inverted fluorescence microscope (Nikon, Tokyo, Japan).
OGT activity assay with HPLC
OGT was expressed in E. coli and purified by nickel affinity
chromatography and gel filtration as in previous methods (40,
41). The reaction mixtures containing 200 M CKII peptide
(KKKYPGGSTPVSSANMM), 100 nM ncOGT, 12.5 mM MgCl2,
1 mM UDP-GlcNAc, buffer (150 mM NaCl, 20 mM Tris-HCl, 1
mM EDTA, 2.5 mM tris(hydroxypropyl)phosphine, pH 7.4) and
the indicated concentrations of luteolin were incubated at 37 °C
for 30 min. After quenching by the addition of an equal volume
of methanol, the reaction mixtures were centrifuged at
12,000  g for 30 min. The supernatants (40 l) were loaded
onto an Agilent 1260 Infinity HPLC system to quantify the yield
based on the integrated areas of glycopeptide product and pep-
tide substrate. The reverse-phase chromatographic column
was a Zorbax SB-C18 stable bond analytical column (4.6 mm 
250 mm, 5 m; Agilent), preceded by a Zorbax SB-C18 analyt-
ical guard column (4.6 mm  12.5 mm, 5 m; Agilent). Mobile
phase A consisted of 0.1% TFA in H2O, and mobile phase B
consisted of 0.1% TFA in MeCN. The components were eluted
using a gradient (flow rate at 1 ml/min; at 0 min elution solvent
mixture A/B  90/10; at 20 min elution solvent mixture A/B 
70/30; wavelength  214 nm). Each reaction was repeated three
times.
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Particle formation was measured using a particle size ana-
lyzer (Z90s, Malvern Instruments Ltd., Malvern, UK). Aggrega-
tor (50 –1000 nm) sizes were measured in 25 mM HEPES buffer
with different concentrations of Triton X-100 (v/v). Experi-
ments were repeated three times, and each histogram shows a
single representative sample.
A, sAPP, and sAPP ELISA
For HEK 293T, HEK 293T-APP Swe, CHO-K1, CHO-ldlD,
and other cells expressing exogenous APP or not, the correspond-
ing cell medium or lysates were then harvested, and A was quan-
tified using human amyloid assay kits for A40, A42, and A 1-x
(IBL, Gumma, Japan) according to the manufacturer’s protocols.
sAPP and sAPP were tested using a human sAPP and sAPP
kit (ExCell Bio, Shanghai, China) according to the protocols.
Mice
APP/PS1 transgenic mice (a total of 10, male) were obtained
from the Model Animal Research Center of Nanjing University
(B6C3-Tg (APPswe, PSEN1dE9)85Dbo/MmJNju). All of the
experiments were performed according to the guidelines estab-
lished by the ethics committee of Shanghai Jiao Tong Univer-
sity. The mice were housed two or three per cage with free
access to water and food in a temperature-controlled room and
under natural lighting conditions with a 12/12-h light/dark
cycle (lights on at 7:00). Mice were intraperitoneally injected
with luteolin (50 mg/kg/day) or PBS from 4 to 6 months of age,
a period in which A has substantially emerged. The mice were
then sacrificed, and the obtained brain homogenates of each
mouse was extracted with 1% Triton X-100 and analyzed for
APP by immunoprecipitation (anti-C-T15 antibody) and for
total A, A40, and A42 by ELISA.
Statistical analysis and Western blot quantification
All experiments were performed at least twice in duplicate or
triplicate with comparable results; the data are presented as the
mean  S.D. Statistical analysis was conducted using one-way
or two-way ANOVA with Bonferroni’s multiple-comparison
tests or two-tailed Student’s t test; statistical significance is indi-
cated as follows: *, p  0.05; **, p  0.01; ***, p  0.001. The
density of the bands was obtained in the linear range by choos-
ing the suitable exposure time and followed by quantification
by using ImageJ (Rawak Software, Inc.).
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